The 2025 US auto tariffs split Canada’s industry: assembly plants lost shifts and products while USMCA-compliant parts makers thrived. Plant-by-plant analysis and the CUSMA review.
Startup · Topic
Canada Company Stories — Page 2
Expert guides, analysis and tool comparisons on Canada Company Stories from the kurums.com Startup desk — written for business decision-makers and updated as the market moves.
- 55 guides
- 11 subtopics
- Updated Oct 20, 2026
Canada Banking & Finance 5
Canada Trade, Tariffs & US Relations 5
Canada Founders & Dynasties 5
Canada Real Estate & Housing 5
Canada Manufacturing & Automotive 5
Canada Transport & Infrastructure 5
Canada Tech & Software 5
Canada Retail & Consumer 5
Canada Mining & Critical Minerals 5
Canada Energy & Oil Sands 5
Canada Healthcare, Cannabis & Life Sciences 5
All guides · page 2
Canada’s C$50bn EV Battery Bet: Volkswagen St. Thomas, Stellantis-LG and the Northvolt Collapse
Canada promised about C$50bn to anchor an EV battery industry. Northvolt is bankrupt, Honda has suspended, Volkswagen is delayed to 2029. What survives and what was lost.
Magna International: The Ontario Parts Giant Caught Between Detroit, Tariffs and EVs
Magna booked US$42bn of 2025 sales and record Q2 2026 earnings despite tariffs, Fisker losses and EV write-downs. How the Stronach-built giant compares with Linamar.
Apotex: The Sherman Family, Generic Drugs, an Unsolved Murder and a 2026 IPO
How Barry Sherman built Apotex on patent challenges, what followed the 2017 murders, and what the June 2026 TSX IPO reveals about Canada’s largest drug maker.
Telus Health, Maple and the Private-Medicine Debate Inside Canada’s Public System
Telus Health’s LifeWorks deal, Maple’s paid virtual visits and the LifeLabs sale explain where private money is allowed inside Canada’s public health system.
Bausch Health: Living With Valeant’s Legacy of Debt, Xifaxan and a Stalled Bausch + Lomb Split
Valeant’s roll-up, its collapse, and Bausch Health’s decade-long turnaround: US$20bn of debt, Xifaxan’s 2028 patent cliff and the unfinished Bausch + Lomb split.
AbCellera and Vancouver’s Biotech Cluster: From COVID Antibodies to a Long Rebuild
How AbCellera turned a COVID antibody windfall into an internal pipeline, and why Zymeworks, Xenon and Stemcell make Vancouver Canada’s leading biotech cluster.
Canada’s Cannabis Bust: How Canopy Growth, Tilray and Aurora Burned Billions After Legalisation
From Constellation’s C$5bn Canopy bet to Curaleaf’s hostile bid for Aurora: how Canada’s cannabis boom turned into a bust and what survivors look like in 2026.
Beyond the US: Canada’s Push to Diversify Exports to Europe, Asia and the Indo-Pacific
How Canada is trying to cut its dependence on the US market through CETA, CPTPP, the 2026 China arrangement, India’s CEPA talks, LNG and critical minerals diplomacy.
Alberta vs Ottawa: Pipelines, Emissions Caps and the 2026 Sovereignty Referendum
The 2026 Alberta referendum, the Canada-Alberta MOU, the C$35-44 billion Pacific Link pipeline and the equalisation grievance: how the energy sovereignty dispute played out.
Tearing Down Interprovincial Barriers: Canada’s One Canadian Economy Act
Bill C-5, the mutual recognition agreement, direct-to-consumer alcohol and trucking rules: what Canada has done about internal trade barriers since 2025 and what is left.
Canada’s Mortgage Renewal Cliff: Five-Year Terms, Variable Rates and the Big Banks
Canada’s five-year mortgage structure, the 2024–26 renewal wave, Bank of Canada cuts, the stress test, OSFI loan-to-income limits and the latest arrears data.
